Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Randomized Phase 2 Study of Weekly Carfilzomib 70 Mg/m2 and Dexamethasone Plus/Minus Cyclophosphamide in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients (GEM-KyCyDex)

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-140934

Published: 2020

Journal Articles

ANCHOR (OP-104): Melflufen Plus Dexamethasone (dex) and Daratumumab (dara) or Bortezomib (BTZ) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI) - Updated Efficacy and Safety

Enrique M. Ocio, MDPhD, Yvonne A. Efebera, MD MPH, Roman Hájek, MD PhD, Miquel Granell, MD, Vladimir Maisnar, MD, Jan Straub, MD, Jean-Richard Eveillard, MD, Lionel Karlin, MD, Vincent Ribrag, MD, María-Victoria Mateos, MD PhD, Albert Oriol, Malin Sydvander, MSc, Stefan Norin, MD, Sofia Mannikko, MSc, Luděk Pour, MD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-135991

Published: 2020

Journal Articles

ANCHOR (OP-104): Updated Efficacy and Safety from a Phase 1/2 Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD or a Proteasome Inhibitor (PI)

Enrique M. Ocio, Yvonne A. Efebera, MD MPH, Miquel Granell, MD, Roman Hajek, MD, Vladimir Maisnar, MD, Lionel Karlin, MD, María-Victoria Mateos, MD PhD, Paul G. Richardson, MD, Albert Oriol, MD, Stefan Norin, MD, Malin Sydvander, MSc, Jakob Obermüller, MSc, Luděk Pour, MD

Blood (2019) 134 (Supplement_1): 3124.

https://doi.org/10.1182/blood-2019-124815

Published: 2019

Journal Articles

VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Definitive Results of a Randomized Phase 3 Pethema/GEM Study

Blood (2018) 132 (Supplement 1): 126.

https://doi.org/10.1182/blood-2018-99-111924

Published: 2018

Journal Articles

The OP-104 Anchor Study: A Phase 1/2 Study of Safety and Efficacy of Melflufen and Dexamethasone in Combination with Either Bortezomib or Daratumumab in Patients with Rrmm; First Report on Phase 1 Data

Blood (2018) 132 (Supplement 1): 1967.

https://doi.org/10.1182/blood-2018-99-112983

Published: 2018

Journal Articles

Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenström's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATE TM )

Blood (2015) 126 (23): 2745.

https://doi.org/10.1182/blood.V126.23.2745.2745

Published: 2015

Journal Articles

Usefulness of Serum-Free-Light-Chains-Ratio (SFLCR) and Serum Heavy-Light-Chains-Ratio (SHLCR) in Multiple Myeloma in the Context of Three GEM/Pethema Clinical Trials

Blood (2015) 126 (23): 2962.

https://doi.org/10.1182/blood.V126.23.2962.2962

Published: 2015

Journal Articles

Persistent Benefit of VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Long-Term Follow-up of a Randomized Phase 3 Pethema/GEM Study

Blood (2014) 124 (21): 3457.

https://doi.org/10.1182/blood.V124.21.3457.3457

Published: 2014

Journal Articles

Kinetics of Response to Bortezomib/Thalidomide/Dexamethasone (VTD) in Multiple Myeloma: Implications for the Choice and Design of Pretransplantation Induction Regimens

Blood (2014) 124 (21): 2108.

https://doi.org/10.1182/blood.V124.21.2108.2108

Published: 2014

Journal Articles

Long-Term Follow-Up Of Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation For High Risk Follicular Lymphoma

Silvana Novelli, MD, Albert Esquirol, MD, Javier Briones, MD, Pilar Leoz, MD, Rodrigo Martino, MD, PhD, Garrido Ana, MD, Irene Garcia, MD, Saavedra Silvana, Miquel Granell, MD, Carol Moreno, MD, Salut Brunet, MD, PhD, Jorge Sierra, MD, PhD

Blood (2013) 122 (21): 5519.

https://doi.org/10.1182/blood.V122.21.5519.5519

Published: 2013

Journal Articles

Analysis of Zoledronic ACID Therapy for Patients with Multiple Myeloma with Asymptomatic Biochemical Relaps.

Ramón García-Sanz, Albert Oriol, Javier De La Rubia, MD, Luis Palomera, MD, Paz Ribas, Miguel Teodoro Hernández, Maria José Moreno, Joan Bargay, Angel Ramírez, Ana Isabel Teruel, María Jesús Blanchard, Mercedes Gironella, MD, Miquel Granell, MD, Eugenia Abella, J.F. San Miguel

Blood (2012) 120 (21): 2967.

https://doi.org/10.1182/blood.V120.21.2967.2967

Published: 2012

Journal Articles

Maintenance Therapy After Stem-Cell Transplantation for Multiple Myeloma with Bortezomib/Thalidomide Vs. Thalidomide Vs. alfa2b-Interferon: Final Results of a Phase III Pethema/GEM Randomized Trial

Blood (2012) 120 (21): 334.

https://doi.org/10.1182/blood.V120.21.334.334

Published: 2012

Journal Articles

A Phase III PETHEMA/GEM Randomized Trial of Postransplant (ASCT) Maintenance in Multiple Myeloma: Superiority of Bortezomib/Thalidomide Compared with Thalidomide and Alfa-2b Interferon,

Blood (2011) 118 (21): 3962.

https://doi.org/10.1182/blood.V118.21.3962.3962

Published: 2011

Journal Articles

Gene Expression Profiling Distinguishes Essential Thrombocythemia from Polycythemia Vera Patients and Identifies a Common Expressed Set of Genes in Relation to JAK2V 617F Status

Eulalia Puigdecanet, Blanca Espinet, PhD, Juan Jose Lozano, PhD, Lauro Sumoy, PhD, Beatriz Bellosillo, PhD, Miquel Granell, MD, Alberto Alvarez-Larrán, MD, PhD, Leonor Arenillas, MD, Francesc Sole, PhD, Sergi Serrano, MD, PhD, Francisco Cervantes, MD, PhD, Carles Besses, MD, PhD, Lourdes Florensa, MD, PhD

Blood (2008) 112 (11): 2788.

https://doi.org/10.1182/blood.V112.11.2788.2788

Published: 2008

Journal Articles

Analysis of microRNA Patterns in Hodgkin’s Lymphoma (HL).

Alfons Navarro, PhD, Anna Gaya, MD, Aina Pons, PhD, Pau Abrisqueta, MD, Bernat Gel, PhD, Antonio Martinez, MD, PhD, Armando Lopez-Guillermo, MD, PhD, Carmen Martinez, MD, PhD, Miquel Granell, MD, Rosa Artells, PhD, Sonia Jansa, PhD, Alvaro Urbano-Ispizua, MD, PhD, Emili Montserrat, MD, PhD, Mariano Monzo, MD, PhD

Blood (2006) 108 (11): 474.

https://doi.org/10.1182/blood.V108.11.474.474

Published: 2006

Journal Articles

Donor’s Mannan-Binding Lectin (MBL) Gene Polymorphism Is Associated with Invasive Fungal Infection Following Allogeneic Stem Cell Transplantation.

Miquel Granell, MD, Alvaro Urbano-Ispizua, MD, Francisco Lozano, MD, Montserrat Rovira, MD, Francesc Fernandez-Aviles, MD, Mar Ortega, MD, Carla Uriburu, MD, Carme Talarn, MD, Carmen Martinez, MD, Belen Suarez, Anna Guardia, MD, Enric Carreras, MD, Emili Montserrat, MD

Blood (2004) 104 (11): 2220.

https://doi.org/10.1182/blood.V104.11.2220.2220

Published: 2004

NARROW

Randomized Phase 2 Study of Weekly Carfilzomib 70 Mg/m2 and Dexamethasone Plus/Minus Cyclophosphamide in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients (GEM-KyCyDex)

ANCHOR (OP-104): Melflufen Plus Dexamethasone (dex) and Daratumumab (dara) or Bortezomib (BTZ) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI) - Updated Efficacy and Safety

ANCHOR (OP-104): Updated Efficacy and Safety from a Phase 1/2 Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD or a Proteasome Inhibitor (PI)

VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Definitive Results of a Randomized Phase 3 Pethema/GEM Study

The OP-104 Anchor Study: A Phase 1/2 Study of Safety and Efficacy of Melflufen and Dexamethasone in Combination with Either Bortezomib or Daratumumab in Patients with Rrmm; First Report on Phase 1 Data

Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenström's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATE TM )

Usefulness of Serum-Free-Light-Chains-Ratio (SFLCR) and Serum Heavy-Light-Chains-Ratio (SHLCR) in Multiple Myeloma in the Context of Three GEM/Pethema Clinical Trials

Persistent Benefit of VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Long-Term Follow-up of a Randomized Phase 3 Pethema/GEM Study

Kinetics of Response to Bortezomib/Thalidomide/Dexamethasone (VTD) in Multiple Myeloma: Implications for the Choice and Design of Pretransplantation Induction Regimens

Long-Term Follow-Up Of Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation For High Risk Follicular Lymphoma

Analysis of Zoledronic ACID Therapy for Patients with Multiple Myeloma with Asymptomatic Biochemical Relaps.

Maintenance Therapy After Stem-Cell Transplantation for Multiple Myeloma with Bortezomib/Thalidomide Vs. Thalidomide Vs. alfa2b-Interferon: Final Results of a Phase III Pethema/GEM Randomized Trial

A Phase III PETHEMA/GEM Randomized Trial of Postransplant (ASCT) Maintenance in Multiple Myeloma: Superiority of Bortezomib/Thalidomide Compared with Thalidomide and Alfa-2b Interferon,

Gene Expression Profiling Distinguishes Essential Thrombocythemia from Polycythemia Vera Patients and Identifies a Common Expressed Set of Genes in Relation to JAK2V 617F Status

Analysis of microRNA Patterns in Hodgkin’s Lymphoma (HL).

Donor’s Mannan-Binding Lectin (MBL) Gene Polymorphism Is Associated with Invasive Fungal Infection Following Allogeneic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only